Literature DB >> 1817037

Type C Niemann-Pick disease: use of hydrophobic amines to study defective cholesterol transport.

C F Roff1, E Goldin, M E Comly, A Cooney, A Brown, M T Vanier, S P Miller, R O Brady, P G Pentchev.   

Abstract

Niemann-Pick Type C (NPC) disease is a cholesterol lipidosis resulting from defective postlysosomal cholesterol transport. In normal cells this segment of cholesterol trafficking is inhibited by treatment with either U18666A or imipramine. Other compounds are also capable of blocking postlysosomal cholesterol transport: stearylamine, RV-538, and sphinganine inhibit low-density lipoprotein-induced esterification of cholesterol and cause unesterified cholesterol to accumulate in perinuclear vesicles. These vesicles can be stained with filipin to give a staining pattern indistinguishable from that seen in NPC fibroblasts. Because all of these compounds are hydrophobic amines, we conclude that most, if not all, hydrophobic amines block the postlysosomal transport of cholesterol. These results also raise the possibility that an endogenous amine, e.g., sphinganine, may inhibit cholesterol transport in NPC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1817037     DOI: 10.1159/000112179

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  33 in total

1.  Modulation of protein kinase C by endogenous sphingosine: inhibition of phorbol dibutyrate binding in Niemann-Pick C fibroblasts.

Authors:  C Rodriguez-Lafrasse; R Rousson; S Valla; P Antignac; P Louisot; M T Vanier
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

Review 2.  The potential of histone deacetylase inhibitors in Niemann - Pick type C disease.

Authors:  Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  FEBS J       Date:  2013-09-23       Impact factor: 5.542

3.  Fluorescence image screening for chemical compounds modifying cholesterol metabolism and distribution.

Authors:  Reiko Ishitsuka; Tamio Saito; Hiroyuki Osada; Yoshiko Ohno-Iwashita; Toshihide Kobayashi
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

4.  Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction.

Authors:  Ryan S Funk; Jeffrey P Krise
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

5.  Amyloid-β metabolism in Niemann-Pick C disease models and patients.

Authors:  Niklas Mattsson; Maria Olsson; Mikael K Gustavsson; Marko Kosicek; Martina Malnar; Jan-Eric Månsson; Maria Blomqvist; Johan Gobom; Ulf Andreasson; Gunnar Brinkmalm; Charles Vite; Silva Hecimovic; Caroline Hastings; Kaj Blennow; Henrik Zetterberg; Erik Portelius
Journal:  Metab Brain Dis       Date:  2012-09-01       Impact factor: 3.584

6.  Comparison of effects of U18666A and enantiomeric U18666A on sterol synthesis and induction of apoptosis.

Authors:  Richard J Cenedella; Patricia S Sexton; Kathiresan Krishnan; Douglas F Covey
Journal:  Lipids       Date:  2005-06       Impact factor: 1.880

Review 7.  Sphingolipid metabolites: members of a new class of lipid second messengers.

Authors:  S Spiegel; S Milstien
Journal:  J Membr Biol       Date:  1995-08       Impact factor: 1.843

Review 8.  Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes.

Authors:  Richard J Cenedella
Journal:  Lipids       Date:  2009-05-14       Impact factor: 1.880

9.  U18666A inhibits intracellular cholesterol transport and neurotransmitter release in human neuroblastoma cells.

Authors:  S M Sparrow; J M Carter; N D Ridgway; H W Cook; D M Byers
Journal:  Neurochem Res       Date:  1999-01       Impact factor: 3.996

10.  Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning.

Authors:  Nuno Rocha; Coenraad Kuijl; Rik van der Kant; Lennert Janssen; Diane Houben; Hans Janssen; Wilbert Zwart; Jacques Neefjes
Journal:  J Cell Biol       Date:  2009-06-29       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.